Premium
Dynamics of propranolol dosing schedules
Author(s) -
Coelho J B,
Dvornik D,
Mullane J F,
Kaufman J,
Simon J,
Krantz K D,
Lee T Y,
Perdue H S,
Weidler D
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.195
Subject(s) - dosing , propranolol , blockade , crossover study , clinical pharmacology , medicine , pharmacology , plasma concentration , anesthesia , placebo , receptor , alternative medicine , pathology
Kinetic and dynamic data from 27 healthy male subjects were evaluated in a double‐blind, randomized, double‐crossover study to test the hypothesis that 180 mg/day propranolol twice and three times a day would provide much the same plasma levels and β 1 ‐blockade. The data indicate that propranolol twice rather than three times a day should be favored when β 1 ‐blockade is needed in therapy. The dynamic efficacy of the two schedules was the same and maximum concentration, AUC 0–24 , and 0‐hr plasma propranolol values were higher after twice‐than after three‐times‐daily dosing. The degree of β 1 ‐blockade (reduction in exercise tachycardia) was much the same on both dosing regimens at trough concentrations. These data indicate that both twice‐ and three‐times‐a‐day dosing schedules provide well‐sustained 24‐hr β‐blockade and are probably interchangeable for therapeutic purposes. Clinical Pharmacology and Therapeutics (1983) 34, 440–447; doi: 10.1038/clpt.1983.195